Severe and/or symptomatic refractory concurrent infection other than EBV
Patients must not have had history of severe toxicity and intolerance to or hypersensitivity to irinotecan or any other study drug; patients must not have had a severe infusion-related reaction during any prior therapy with pertuzumab or trastuzumab
Prior severe reaction to treatment with a human antibody that cannot be managed with standard supportive measures.
Severe valvular heart disease
Severe coexisting or terminal systemic disease that may interfere with the conduct of the study
Severe comorbidities:
Significant valvular disease, severe regurgitation, or stenosis by imaging independent of symptom control with medical intervention or history of valve replacement
Severe comorbidities:
Severe medical comorbidities precluding endoscopy
Patients with known GPD deficiency, severe psoriasis, porphyria, macular degeneration or severe diabetic retinopathy are ineligible because of the potential for greater HCQ toxicity
T-LGL judged by the investigator to require therapy based upon:  \r\n*Severe neutropenia (absolute neutrophil count < /microL)\r\n*Moderate neutropenia (absolute neutrophil count < /microL) with recurrent infections\r\n*Symptomatic or transfusion dependent anemia\r\n*Severe thrombocytopenia (< ,/microL)\r\n*Hepatic infiltration resulting in abnormal liver function tests\r\n*Symptomatic splenomegaly
Severe symptomatic depression and or anxiety (study physician discretion)
Severe hip disease precluding the use of dorsolithotomy position
Active uncontrolled infection or severe infectious disease, such as severe pneumonia, meningitis, septicemia, or methicillin resistant staphylococcus aureus infection
Has active uncontrolled infection or severe infectious disease, such as severe pneumonia, meningitis, or septicemia.
History of severe eczema (as determined by the investigator) requiring medical treatment
Patients who experienced a severe systemic reaction or side-effect as a result of a previous vaccination with vaccinia
Subject has tolerated prior dose of modified CAR T cell infusion without experiencing a severe toxicity; OR if patient did have a severe toxicity, they have fully recovered to baseline
Patients with severe allergies to piperacillin-tazobactam, cefepime, aztreonam or vancomycin; severe reactions include anaphylaxis and Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN)
History of cutaneous or mucocutaneous reactions, or diseases in the past, due to any cause, severe enough to cause hospitalization or an inability to eat or drink for >  days; this exclusion relates to the long-term possibility of severe cutaneous or mucocutaneous reactions to rituximab that might occur at increased frequency in participants who have had severe skin disease or reactions in the past
Have severe vomiting, diarrhea, or other severe gastrointestinal illness within  hours prior to the first dose of study treatment that would preclude administration of oral medication.
GROUP : Progressive gastrointestinal disease as defined by all of the following items:\r\n* Disease duration of scleroderma =<  years.\r\n* Documented severe malabsorption syndrome requiring nutritional support; severe malabsorption syndrome is > % weight loss and on total parenteral nutrition (TPN) or enteral feedings\r\n* High score on distention/ bloating scale (>= . out of .) on gastrointestinal (GI) questionnaire
Significant valvular disease; severe regurgitation or stenosis by imaging independent of symptom control with medical intervention; or history of valve replacement.
iC-CAR CELL INFUSION: Severe systemic uncontrolled disease or toxicities that develop after lymphodepletion may prompt exclusion from cell infusion at the discretion of the investigator
Active uncontrolled infection or severe infectious disease, such as severe pneumonia, meningitis, septicemia, or methicillin resistant Staphylococcus aureus infection
Severe or uncontrolled concurrent disease, infection or comorbidity.
Pregnant or lactating subjects. * Note: Major surgery defined as requiring a general anesthesia or respiratory assistance; involving openings into the great cavities of the body, organs removed, or normal anatomy altered; implying risks of severe hemorrhage; implying risk for life of the patient or severe disability.
Known severe congenital or acquired cellular or humoral immunodeficiency such as common variable immunodeficiency.
Patients with unstable or severe intercurrent medical conditions such as severe heart or lung disease
Evidence of severe concurrent disease requiring treatment
Have major abnormalities documented by ECHO with Doppler (for example, moderate or severe heart valve function defect including moderate or severe valve stenosis or regurgitation, left ventricular ejection fraction <%, evaluation based on the institutional lower limit of normal, septal aneurysm or other heart aneurysm, any aneurysm of the major vessels or any condition that results in increased risk of aneurysm (eg, Marfan syndrome, patent foramen ovale [PFO]).
Prior severe skin reaction (toxic epidermal necrosis) with immunomodulating agents
Patients with unstable or severe intercurrent medical conditions such as severe heart or lung disease
Subject has history of severe infusion reactions related to prior biologics or antibody-based treatments
Patients who have previously had a severe side effect, such as agranulocytosis and neutropenia, in conjunction with previous mebendazole or benzimidazole class drug for a parasitic infection
Patients with any other severe and/or uncontrolled concurrent disease affecting the cardiovascular system, liver, kidneys, hematopoietic system or else considered as clinically important by the investigator and that could be incompatible with patient's participation in this trial or would likely interfere with study procedures/results or compromise compliance with the protocol.
History of inflammatory colitis or other active severe comorbidities
Prior severe infusion reaction (bronchospasm, stridor, urticaria and/or hypotension) to a taxane therapy
Severe psychiatric illness or mental deficiency sufficiently severe as to make compliance with the transplant treatment unlikely and informed consent impossible
Hematocrit > %, untreated severe obstructive sleep apnea, uncontrolled or poorly controlled heart failure (per Endocrine Society Clinical Practice Guidelines)
Any contraindications to angiography and hepatic artery catheterization such as:\r\n* History of severe allergy or intolerance to any contrast media, narcotics, sedatives, or atropine that cannot be corrected or premedicated\r\n* Bleeding diathesis, not correctable by usual forms of therapy\r\n* Severe peripheral vascular disease that would preclude catheterization
Satisfactory cardiopulmonary function (no history of severe congestive heart failure or severe pulmonary disease, as indicated by clinically acceptable risks to undergo major abdominal - cytoreductive surgery)
Individuals with severe or uncontrolled recurrent cutaneous infections who are considered at elevated risk for serious infection on anakinra therapy will be excluded per physician discretion
Patients should have an indication for therapy for their disease such as transfusion dependence or morbidity associated with their cytopenia(s) such as bleeding, severe fatigue, or frequent/multiple infections (eg. neutropenia)
Severe alloimmunization with inability to guarantee a supply of adequate PRBC donors
Patients with severe comorbidities, not related to their EBV-associated malignancy, that would be expected to preclude their survival for the  weeks required to assess response of T cell therapy
History of severe eczema (as determined by the Investigator) requiring medical treatment
Patients in Part E or Part F: history of severe immune-mediated adverse reactions or severe hypersensitivity to pembrolizumab
Any contraindications to angiography and hepatic artery catheterization such as: History of severe allergy or intolerance to any contrast media, narcotics, sedatives, or atropine that cannot be corrected or premedicated; Bleeding diathesis, not correctable by usual forms of therapy; Severe peripheral vascular disease that would preclude catheterization.
Other concurrent severe and/or uncontrolled medical, psychiatric or social conditions that could compromise the safety or compliance of treatment as so judged by treating physician\r\n* Examples include but are not limited to:\r\n** History of severely impaired lung function defined as spirometry and diffusion capacity of carbon monoxide (DLCO) that is =< % of the normal predicted value and/or  saturation that is =< % at rest on room air\r\n** Uncontrolled diabetes mellitus consistent fasting blood glucose readings >  mg/dL or <  mg/dL); use of diabetic medications is permitted\r\n** Hyperlipidemia (total cholesterol > -; triglycerides > ); use of lipid lower lowering agents is permitted\r\n** Other: e.g. severe infection, severe malnutrition, ventricular arrhythmias, known active vasculitis of any cause, tumor invasion of any major blood vessel, severe chronic liver or renal disease, active upper GI tract ulceration
Serious underlying medical condition or infection other than HIV that would contraindicate SC-EPOCH-R; examples include, but are not limited to:\r\n* Severe AIDS-related wasting\r\n* Severe intractable diarrhea\r\n* Active inadequately treated opportunistic infection of the central nervous system (CNS)\r\n* Primary CNS lymphoma
Current severe urinary incontinence, hydronephrosis, severe voiding dysfunction, any level of urinary obstruction requiring indwelling/condom catheters
Active uncontrolled infection or severe infectious disease, such as severe pneumonia, meningitis, or septicemia that require IV antibiotics within  weeks of starting study treatment
The patient has concurrent severe and/or uncontrolled medical disease that could compromise participation in the study (i.e., uncontrolled diabetes, severe infection requiring active treatment, severe malnutrition, chronic severe liver or renal disease).
Patients with an active infection or severe hematological, neurological, or other uncontrolled disease.
Severe organ failures or diseases, including: clinically relevant coronary disease, myocardial infarction or any other relevant cardiovascular disorder within  months before study entry, severe psychiatric illness and severe infection.
Personal or family history of severe sickle cell disease or variant (unless donor has tested negative); testing for the presence of hemoglobin S is not required
Evidence of severe concurrent disease requiring treatment.
Subjects receiving investigational study drug for any indication or immunological-based treatment for any reason (Filgrastim may be used for prevention of severe neutropenia).
Have severe vomiting, diarrhea, or other severe gastrointestinal illness within  hours prior to the first dose of study treatment that would preclude administration of oral/enteral medication.
Severe uncontrolled malabsorption condition or disease (i.e. grade II/III diarrhea, severe malnutrition, short gut syndrome)
Patients who have severe hypersensitivity to irinotecan hydrochloride (HCl)
AIDS-related syndromes, infectious or otherwise, if perceived to cause excessive risk for morbidity post-HSPC infusion, as determined by the PI; examples include, but not limited to:\r\n* Severe AIDS-related wasting\r\n* Severe intractable diarrhea\r\n* Active inadequately treated opportunistic infection of the central nervous system (CNS)\r\n* Primary CNS lymphoma
History of cutaneous or mucocutaneous reactions, or diseases in the past, due to any cause, severe enough to cause hospitalization or an inability to eat or drink for >  days; this exclusion relates to the long-term possibility of severe cutaneous or mucocutaneous reactions to rituximab that might occur at increased frequency in participants who have had severe skin disease or reactions in the past
PHASE I: History of intolerance to capecitabine at doses =<  mg/m^ BID, as defined by documented >= grade  hand-foot syndrome, documented severe diarrhea requiring hospitalization, or other documented severe adverse events (AEs) attributable to capecitabine
PHASE II: History of intolerance to capecitabine at doses below  mg/m^ BID, as defined by documented >= grade  hand-foot syndrome; documented severe diarrhea requiring hospitalization; or other documented severe AEs attributable to capecitabine
Unstable medical conditions (eg, myocardial ischemia, active gastrointestinal bleed, severe congestive heart failure, anticipated need for major surgery within  months of randomization, coexisting chronic anemia unrelated to PNH)
Unstable medical conditions (eg, myocardial ischemia, active gastrointestinal bleed, severe congestive heart failure, anticipated need for major surgery within  months of randomization, coexisting chronic anemia unrelated to PNH).
Significant valvular disease; severe regurgitation or stenosis by imaging independent of symptom control with medical intervention; or history of valve replacement;
Active uncontrolled infection or severe infectious disease, such as severe pneumonia, meningitis, or septicemia.
Severe underlying chronic illness or disease
Other concurrent severe and/or uncontrolled medical disease, psychiatric illness, or social situation, which could compromise safety of treatment as so judged by the treating physician; Note: this includes but is not limited to: severely impaired lung function, uncontrolled diabetes (history of consistent blood glucose readings above  mg/dL or less than  mg/dL), severe\r\ninfection, severe malnutrition, ventricular arrhythmias, known active vasculitis of any cause, tumor invasion of any major blood vessel, chronic liver or renal disease, and active upper GI tract ulceration
Subject has a documented severe congenital or acquired immunodeficiency;
Patient has any severe psychiatric disease that would interfere with participation in the trial as determined by the study investigator
The patient has concurrent severe and/or uncontrolled medical disease that could compromise participation in the study (i.e., uncontrolled diabetes, severe infection requiring active treatment, severe malnutrition, chronic severe liver or renal disease)
Severe or uncontrolled medical issues
Subjects should not have severe peritoneal metastases. The following criteria were applied:
Patients who have previously had a severe side effect, such as agranulocytosis and neutropenia, in conjunction with previous mebendazole or benzimidazole class drug for a parasitic infection
Any other concurrent severe known disease (except carcinoma in-situ) concurrent severe and/or uncontrolled medical condition including congestive heart failure grade III or IV according to the NYHA classification or with ejection fraction < %, etc.
Patients with unstable or severe intercurrent medical conditions such as severe heart or lung disease
Severe valvular stenosis (e.g., aortic or mitral stenosis with a valve area <. cm) or severe congenital heart disease
The donor currently has or had a history of any clinically relevant gastrointestinal, hematologic, respiratory, psychiatric, renal, hepatic, cardiac, metabolic (eg, fructose intolerance), neurological, or any other disease or condition which may influence the physiological metabolic turnover (eg, severe endocrine diseases, febrile condition, severe infections
History of severe side effects toimmunotherapy
Severe, active co-morbidity: (e.g. cardiac disease; respiratory disease; chronic hepatitis; hemtological and bone marrow diseases; severe malabsoprtion; human immunodeficiency virus).
History of severe reactions to cetuximab and/or panitumumab (except for G rash and G hypomagnesaemia)
Involvement of one or more of the following organ systems (renal, neurologic, hematologic, cardiac, pulmonary, gastrointestinal) of moderate-to-severe severity as indicated by an A or  B score on the British Isles Lupus Assessment Group (BILAG), a  or higher on the Physician Global Assessment, or severe enough to require hospitalization if the organ involvement was not captured on either the BILAG or Systemic Lupus Erythematosus Activity Measure (SLAM) instruments
Patients with severe hematologic, neurologic, or other uncontrolled disease
Severe, active co-morbidity (e.g. cardiac disease; respiratory disease; chronic hepatitis; hematological and bone marrow diseases; severe malabsorption)
Patient shows evidence of severe hepatic veno-occlusive disease (VOD) or sinusoidal obstruction.
Have a primary or other severe immunodeficiency which predisposes to rapid progression to disseminated AdV disease
Open fractures with severe contamination.
Active uncontrolled infection or severe infectious disease, such as pneumonia, meningitis, septicemia, or methicillin-resistant Staphylococcus aureus infection.
Known severe ulcer disease
Severe conduction disturbance
Severe conduction disturbances
Prior unanticipated severe reaction to fluoropyrimidine therapy
Patients with severe medical or psychiatric diseases are INELIGIBLE (patients with stable chronic diseases such as high cholesterol or hypertension ARE eligible); examples of problems that would make patients INELIGIBLE include severe heart failure, or hypoxia due to severe lung disease
Severe concurrent disease;
Concurrent severe uncontrolled illness not related to cancer
Subject has severe granulocytopenia
DONOR: History of hypertension that is not controlled by medication, stroke, or severe heart disease; individuals with symptomatic angina will be considered to have severe heart disease and will not be eligible to be a donor
Uncontrolled, severe infective processes
Severe hepatic dysfunction accompanied by coagulopathy definition:\r\n* Known liver disease AND\r\n* International normalized ratio (INR) > . (except for patients on anticoagulants) AND\r\n* Platelet count < ,/uL without other obvious cause
Patients with an active infection or severe hematological, neurological, or other uncontrolled disease.
Severe sleep disorders (e.g., narcolepsy)
Evidence of severe uncontrolled systemic disease or other comorbidity that precludes liver surgery
Severe sleep disorders (e.g., Narcolepsy)
Contraindications to arteriography and selective visceral catheterization:\r\n* Severe allergy or intolerance to contrast media, narcotics, sedatives, or atropine\r\n* Bleeding diathesis not correctable by usual forms of therapy\r\n* Severe peripheral vascular disease precluding catheterization
Severe musculoskeletal disease: severe muscle or joint disorders due to disease or trauma, amputations, or any condition that significantly impair physical capabilities, as defined by the physician
Severe musculoskeletal disease: severe muscle or joint disorders due to disease or trauma, amputations, or any condition that significantly impair physical capabilities, as defined by the physician
Severe or symptomatic heart disease
Severe cachexia, dizziness, bone pain, or severe nausea (as judged by the investigator)
Severe concurrent illness other than neoplasia
Active or unstable metabolic conditions such as brittle diabetes or severe anemia (hemoglobin <  g/dl)
Severe depression as determined by the investigator
Uncorrected primary obstructive or severe regurgitative valvular disease, nondilated (restrictive) or hypertrophic cardiomyopathy, or significant systemic ventricular outflow obstruction
Severe illness at the time of the clinic visit
Patients with severe symptom distress as assessed by nursing staff.
Satisfactory cardiopulmonary function (no history of severe congestive heart failure or severe pulmonary disease, as indicated by clinically acceptable risks to undergo major abdominal - cytoreductive surgery)
History of gold-induced disorders, including but not limited to, necrotizing enterocolitis, pulmonary fibrosis, exfoliative dermatitis, bone marrow aplasias or other severe hematologic disorders; history of severe allergic or anaphylactic reactions or hypersensitivity to auranofin or other gold compounds
Pre-registration screen of cognition is \severe\ or lower
Severe marital maladjustment that prevents a patient from benefiting from the proposed intervention (<  on the Locke-Wallace Marital Adjustment Test)
Patients with severe organ dysfunction\r\n* On dialysis\r\n* Requiring oxygen (O) at more than  l/min\r\n* Uncontrolled arrhythmia or heart failure\r\n* Veno-occlusive disease (sinusoidal obstruction syndrome)
Evidence of severe uncontrolled systemic disease or other comorbidity that precludes liver or pancreatic surgery
Patients with known severe esophagitis
Participants with the following underlying medical conditions: multiple myeloma, myasthenia gravis, dysproteinemias, severe cardiac disease, aortic stenosis, primary pulmonary hypertension, cardiac arrhythmia, or severe cardiomyopathy. These underlying medical conditions may make the participant more likely to develop a contrast reaction. This is based on the American College of Radiology (ACR) contrast manual version . and hospital policy.
Participants with the following underlying medical conditions: multiple myeloma, myasthenia gravis, dysproteinemias, severe cardiac disease, aortic stenosis, primary pulmonary hypertension, cardiac arrhythmia, or severe cardiomyopathy
Subjects with severe, symptomatic dysphagia (unable to pass solids)
Uncorrected primary obstructive or severe regurgitative valvular disease:\r\n* Nondilated (restrictive); or\r\n* Hypertrophic cardiomyopathy; or\r\n* Significant systemic ventricular outflow obstruction
DONOR: Severe psychiatric illness. Mental deficiency sufficiently severe as to make compliance with the donation procedure unlikely, and making informed consent impossible
Severe neuromusculoskeletal conditions that limit their ability to perform walking exercise (including ataxia, peripheral or sensory neuropathy, unstable bone lesion, severe arthritis, lower limb fractures within  months, lower limb amputation)
Recent or severe mental illness (uncontrolled severe depression or mood symptoms, active hallucinations, or hospitalization in the past month for a psychiatric condition); night and/or swing shift work (which complicates EMA schedules);
Patients with a history of severe allergy including eczema or other exfoliative skin disorder or active skin diseases such as psoriasis, lichen planus, severe acneiform rash, impetigo, varicella zoster, or sepsis among patients or among close social, sexual or domestic contacts; patients with burns or other traumatic or pruritic skin conditions or open wounds should not receive the vaccine until the condition has resolved; surgical scars must be healed
Prior history of severe reactions to oxaliplatin as characterized by the presence of hemodynamic instability, significant respiratory symptoms or potential airway compromise
Concurrent severe and/or uncontrolled medical condition (e.g., severe COPD).
Patients with severe metabolic disorders that would preclude administration of calcitriol
Severe emphysema or COPD: additional testing and PI consent is required
severe cachexia
severe respiratory insufficiency or hypoxia
Severe acute illness
Participants who have any contraindication to iodinated contrast for routine computed tomography (CT) scans including: sickle cell disease, pheochromocystosis, multiple myeloma, severe cardiac disease, aortic stenosis, primary pulmonary hypertension, or severe cardiomyopathy
Has history of herpetic infection, recurrent aphthous ulcer, or other ulcer forming diseases, abscesses, granulomas, or severe gingivitis
Severe allergic disease
Severe coexisting or terminal systemic disease that may interfere with the conduct of the study
Severe respiratory disease
Severe underlying chronic illness or disease (other than breast cancer)
Inability to participate in physical activity because of severe disability (e.g., severe arthritic conditions)
Patients who are considered to be in severe physical or emotional distress based on the assessment by the research staff
Patients who are experiencing severe symptom distress, including severe emotional distress and cognitive dysfunction, which may interfere with study participation; this will be determined by the principle investigator and/or attending physician who is caring for the patient during that visit
has a substantial risk to progress and cause severe complications.
